MINNEAPOLIS, March 27, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it is a Platinum Sponsor and will be exhibiting at the International Veterinary Academy of Pain Management (“IVAPM”) Pain Management Forum to be held April 2nd to April 4th 2023 at the Westin Peachtree Plaza in Atlanta, Georgia.

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.

“The IVAPM Pain Management Forum provides us an excellent event to demonstrate to leading pain management experts in the veterinary profession our innovative medical device for the management of osteoarthritis, Spryng, with OsteoCushion Technology” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We welcome the opportunity to support the IVAPM and participate in this forum to explain the benefits of Spryng and how it may be used to enhance the lives of companion animals.”

For more information about PetVivo Holdings, Inc. please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or visit https://petvivo.com/

Conference Details:

Pain Management Forum Exhibit Details:

International Veterinary Academy of Pain Management (“IVAPM”)

Booth #: 4&5

Dates:

Sunday, April 2, 2023 9:00am – 7:30pm

Monday, April 3, 2023 9:00am – 7:30pm

Tuesday, April 4, 2023 9:00am – 4:00pm

Location: The Westin Peachtree Plaza in Atlanta, Georgia

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG^™ with OsteoCushion^™ technology, a veterinarian-administered, intraarticular injectable medical device for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.

For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or visit https://petvivo.com/.

CONTACT:

John Lai, CEO

PetVivo Holdings, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

(952) 405-6216 

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.